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1. Introduction
The prevalence of skin cancer varies greatly according to the geographic location and is
developing rapidly in Western countries. This type of cancer is most frequent in fair-skinned
people. In Australia, the rate of melanomas increased annually by 6.3% in men and 2.9% in
women between 1959 and 1985. This type of cancer is the most frequent one in fair-skinned
people. Since 1985, the rate has levelled off, which is reassuring even though the incidence of
skin cancer in Australia is the highest in the world [1] (table 1) [2], followed by New Zealand
and Norway [3]. As a comparison, we can look at the rate of non-melanoma skin cancer
(NMSC) in Japan, which is between 1.2 and 5.4 per 100,000, that is to say a factor of 50 compared
to Australia [4]. Skin cancer in children is rare. In teenagers (from 15 to 19 years old) the
prevalence in England is 10 cases per million per year for melanomas and 24 cases per million
per year for NMSC. The risk factors are: a family history of melanomas, Xeroderma pigmento‐
sum [5] and pathologies responsible for states of immunosuppression. Cases of congenital
melanomas are extremely rare [6]. Excessive sun exposure has long been recognised as the
most important environmental factor to be taken into account; indeed, ultra-violet radiation
(UV) is the cause of 90% of NMSC and 67% of melanomas [7]. The high incidence of skin cancer
in certain countries of the world is therefore not just down to chance but has a direct link to
the population's skin type (fair-skinned, blue-eyed people who burn easily, who never tan and
who often have freckles) [8] and to the level of sunshine [9]. Although UV rays only represent
3% of the total radiation which reaches Earth, from a point of view of energy, it is thought that
they account for 10% of light energy [10]. Mountainous regions bring a greater risk of devel‐
oping sunburn, as the quantity of UVB increases by 4% every 300 metres [11], and in a similar
way, the position with relation to the equator is of utmost importance, (the risk is greatest
around the Tropics). UV radiation (UVA and B) causes alterations in DNA by either direct or
indirect actions (by means of an oxidizing stress). The types which react to oxygen can cause
either an increase in cell proliferation or their apoptosis, accordingly [12]. The notion of
© 2013 Couteau and Coiffard; licensee InTech. This is an open access article distributed under the terms of
the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
phototypes, put forward by Fitzpatrick as early as 1975 within the framework of the care of
patients treated with PUVA therapy, is linked to the concept of sun-reactive skin. This scale
enables Caucasian subjects to be classed according to their sensitivity to UV rays. At first, 4
phototypes were established, called I, II, III and IV (Table 2), then this scale was later extended
to include phototypes V (brown skin or Asian skin) and VI (black) [13]. A classification
concerning Japanese people was also drawn up by Kawada [14]. The three corresponding
groups are JI (always burn and rarely tan), JII (burn and tan moderately), JIII (never burn and
always tan). These three groups should be linked to the Caucasian phototypes II, III and IV
[15]. In the 1990s, JP Césarini introduced the notion of melano-compromised subjects (Photo‐
types I and II), melanocompetent subjects (Phototypes III and IV) and melanoprotected
subjects according to their varying capabilities to protect themselves against skin cancer [16].
The best level of photoprotection is reached by black subjects, who are shown to have a low
incidence of skin cancer (1 to 2% of cancers affecting black people are skin cancers compared
to 20 to 30% for Caucasians). The phototypes are linked to melanin, which is a biopolymer
functioning as a filter and which enables black people to produce an SPF (Sun Protection
Factor) of around 13. The dispersion of melanosomes and their lack of degradation throughout
the keratinization process forms an effective barrier. A black person's melanin filters twice as
much UVB radiation as a Caucasian's melanin. The black epidermis is much more protected
than a Caucasian one, as it transmits 7.4% of UVB radiation and 17.5% of UVA radiation
compared to 24 and 55% for a Caucasian epidermis. In terms of Minimal Erythemal Dose
(MED), it can be observed that this dose is between 6 and 33 times higher in black subjects [17].
It is important to create new classifications on a regular basis because of the interbreeding of
races in the population. For example, in 1990, the US Census Bureau registered 6 races and 23
sub-types in the United States; 10 years later, the Census Bureau still counted 6 categories, but
the number of sub-types had increased to 67, creating a multiplicity of sensitivities to the sun
[18]. It seems that precautions taken by people who work outside to protect themselves from
the sun are related to their phototype, as an American study shows that fair-skinned people
are more aware in this respect [19]. The current way of life in industrialized countries goes
hand in hand with an increase in the frequency of the length of exposure to the sun during
leisure time. Contrary to previous centuries where pale skin tones were all the rage, the fashion
of having a sun-tan, which began in the Thirties, is still current. The SUVIMAX study which
was conducted in France in 1994 showed that in the cohort of 7,822 subjects questioned, 196
(110 women and 86 men) had travelled to a country with high levels of sunshine (high UV
index) within the previous year and for a period of at least one month. Women, in particular,
appear to be most concerned with daily exposure to sunshine (more than 2 hours per day) and
admit that "getting a tan" is very important for them [20]. Sunbathing is still popular. Professor
Dubertret is pessimistic and considers that if nothing is done in the way of prevention
campaigns, the rate of skin cancer will double every ten years and a child born in 2000, if he
behaves in the same way as his parents regarding his exposure to the sun, will have a 1 in 75
risk of developing a melanoma and a 1 in 7 risk of developing basocellular cancer [21]. The
behavior of young Europeans tends towards improvement. Indeed, an increase in the use of
sun products throughout exposure can be observed. In 10 years (between 1990 and 2000), the
use of sun products increased from 52 to 63% in boys and from 80 to 87% in girls. It is a pity
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that a minority is still so resistant to using sun products [22]. On the other hand, young
Australians (from 12 – 17 years old) largely ignore prevention campaigns and the use of sun
products decreased between 1993 and 2000 (going from 54 to 36% for teenagers in general and
from 73 to 50% for girls in particular) [23]. A second more optimistic study praises the SunSmart
television advertising campaign, which seems to be bearing fruit [24]. Indeed, the slogans are
well-chosen and are likely to bring about a change of attitude; as proof: « Leave your hat on »
(1991 – 1992), « How to remove a skin cancer » (1996 – 1998) and « No tan is worth dying for:
Clare Oliver » (2008). In short, depending on the panels and on the authors, opinions differ [25].
The fact remains that young people in general, and more particularly young Americans (from
the south of the USA) are stubborn and are still fond of exposing themselves to the sun.
Sunburn at the end of the weekend is not uncommon [26]. A lot of efforts still have to be made,
as only 1/3 of parents questioned say that they prefer activities for their children which avoid
exposure to the sun and confirm that they apply sun products whilst doing beach-based
activities [27]. Public awareness campaigns are necessary, as childhood is a key stage and it is
important to understand that people who do not want to use sun products whilst continuing
to expose themselves to the sun, do so for aesthetic reasons, in order to have a tan [28]. We set
out, therefore, to present a method for topical skin protection: the use of sun products.
Countries Prevalence
France 7/100000
Sweden 11/100000
US 14/100000
Australia 50/100 000
Table 1. Prevalence of skin cancers - 1995 [2]
Phototypes Sensitivity to sunlight
I Always burns, never tans
II Burns easily, tans minimally
III Burns moderately, tans gradually to light brown
IV Burns minimally, always tans well to moderately brown
V Rarely burns, tans profusely to dark
VI Never burns, deeply pigmented
Table 2. Phototypes according to the Fitzpatrick classification
About Suncare Products
http://dx.doi.org/10.5772/55411
129
2. Topical photoprotection
2.1. Definition
There are many methods of sun protection, such as photoprotection by clothing, systemic
photoprotection (medicine and dietary supplements) and topical photoprotection, using sun
products with a variety of dosage forms.
Sun products are used to avoid skin damage due to the sun. These products contain molecules
which can work through absorption or by reflecting UV rays [29].
The classification of sun products as either cosmetics, or as over-the-counter medicines, differs
according to the health authority governing bodies concerned.
The Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS) [The French
Agency for Health Safety and Health Products – equivalent to the FDA – Food and Drugs
Administration (USA) and the MHRA (UK) remains cautious, saying that "Sun products are
effective in the prevention of actinic erythema" It insists, by saying that their preventive effects
concerning photo-ageing and skin cancer is yet to be proved [30]. In France, although the Code
de la Santé Publique (Public Health Code), defines cosmetics in a general way, it does not,
however, give a specific definition for sun products [31].
In the USA, an over-the-counter sunscreen drug product in a form suitable for topical admin‐
istration is generally recognized as safe and effective and is not misbranded if it meets each
condition. Here, we are talking of harmlessness and of efficacy (but without being specific
about possible prevention regarding effects of UV radiation) [32]. This notion of harmlessness
can be found in the Public Health Code [33], in European directives [34] and more recently in
regulation N°1223/2009 [35] which has just been written and whose aim is to suggest a more
legible type of legislation bringing together successive directive demands.
2.2. Which regulatory status for sun products?
2.2.1. Different categories of sun products
As we mentioned earlier, the status of sun product is not unique and differs from country to
country. We will mention more specifically the two main legislations on suncare products,
namely the European and American ones. It should be noted that the indices which may appear
on the packaging of sun products are not the same for European products as they are for
American ones (Table 3). In Europe, all of the products which have an SPF (Sun Protection
Factor) lower than 6 are not considered as sun products (compared to 2 according to American
legislation). The number of categories is bigger in Europe than in the USA (4 large categories
and 8 indices in Europe compared to 3 large categories and an infinite number of indices which
could be seen on the packaging in the USA. In Europe, in order to make the consumer's life
easier and to avoid swamping them with too many indices, a standard index system on
packaging was established. Therefore, on the market, products with indices of 17, 24, 36, 54
etc. cannot be found. The index value is always rounded down. In Europe, the tendency is to
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reduce the number of indices, and the aim of the creation of an index of 50+ concerning all
products which have a determined SPF equal to or higher than 60 was to avoid having indices
higher than 100 on packaging, as this could have led the consumer to believe that the product
provided total protection.
European regulation American regulation
Different
categories of
sunscreens
- Low protection
SPF labelled: 6, 10
- Moderate protection
SPF labelled: 15, 20, 25
- High protection
SPF labelled: 30, 50
- Very high protection
SPF labelled: 50+
- Minimal sun protection product
(2 < SPF < 12)
- Moderate sun protection product
(12 ≤ SPF < 30)
- High sun protection product
(SPF ≥ 30)
Table 3. Different categories of sunscreens
2.2.2. Authorized filters
Whichever legislation is considered, a limited number of filters are authorized in the formula‐
tion of sun products. In Europe, Appendix VI of the Regulation lists the 26 authorized filters,
that is to say 25 organic filters and one screen, titanium dioxide, each one having a maximum
concentration of use (% m/m) and perhaps a list of comments which should feature on the
packaging. In the USA, the original list was made up of 16 filters (15 filters and 1 screen). In the
period from 1997 to 2008, 8 filters recognized safe and effective were gradually added to this list.
The FDA gradually authorized a certain number of products which were synthetized and
patented in Europe in order to beef up the original list. It should be noted that zinc oxide is not
mentioned in Appendix VI of the Regulation (Table 4). The concentration of zinc oxide is therefore
not limited. This, however, remains theoretical, as the limit is imposed by its dosage form, as in
high percentages of concentration, a paste is obtained, which would be difficult to market.
Seventeen filters are currently in common between the European and American legislation.
2.2.3. The combination of different filters or the combination of filters with active ingredients
European formulators have a great deal of freedom. They can combine as many filters as they
want, as long as the combinations are not already patented, of course. They can also combine
filters with active ingredients which have a softening, antioxidizing or soothing effect, etc.
They have to check that the raw material they want to incorporate is not banned and they must
check to see if the material is on a list if regulated ingredients (Appendix III: substances with
restricted use in particular). In the USA, combinations with protectants are authorized within
the limits of the maximum authorized concentrations (Table 5). A skin protectant drug product
is defined as «a drug product that temporarily protects injured or exposed skin or mucous
membrane surfaces from harmful or annoying stimuli, and may help provide relief to such
surfaces».
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INCI name/American name (trade name) Cmax authorized(Europe)
Cmax authorized
(US)
Aminobenzoic acid / 15%
Cinoxate / 3%
Dioxybenzone / 3%
Meradimate / 5%
Trolamine salicylate / 12%
Zinc oxide / 25%
Camphor benzalkonium methosulfate (Mexoryl SO®) 6% /
Homosalate (Eusolex HMS, Néohélipan HMS, Parsol
HMS) 10% 15%
Oxybenzone (Eusolex 4360, Uvinul M40) 10% 6%
Phenylbenzimidazole sulfonic acid, Ensulizole (Eusolex
232, Parsol HS, Néohéliopan Hydro USP) 8% (in acid form) 4%
Terephtalydene dicamphor sulfonic acid, Ecamsule
(Mexoryl SX)
10%
(in acid form) 10%
Butylmethoxydibenzoylmethane (Eusolex 9020, Parsol
178) 5% 3%
Benzylidene camphor sulfonic acid (Mexoryl SL) 6% (in acid form) /
Octocrylene (Uvinul N539T, Eusolex OCR, Parsol 340,
Néohéliopan 303 USP)
10%
(in acid form) 10%
Polyacrylamidomethylbenzylidene camphor (Mexoryl
SW) 6% /
Ethyl hexyl methoxycinnamate, Octinoxate (Uvinul MC
80, Eusolex 2292, Parsol MCX, Néohéliopan AV) 10% 7.5%
PEG-25 PABA (Uvinul P25) 10% /
Isoamyl p-methoxycinnamate, Amiloxate (Néohéliopan
E1000) 10% 10%
Octyl triazone (Uvinul T150) 5% 5%
Drometrizole trisiloxane (Mexoryl XL) 15%
Diethylhexylbutamidotriazone (Uvasorb HEB) 10% 3%
4 -methylbenzylidene camphor, Enzacamene (Eusolex
6300, Néohéliopan MBC, Parsol 5000) 4% 4%
3-benzylidene camphor (Unisol S22) 2% /
Ethylhexylsalicylate, Octisalate (Eusolex OS, Néohéliopan
OS, Dermoblock OS) 5% 5%
Octyl dimethyl PABA, Padimate O (Eusolex 6007) 8% 8%
Benzophenone-4 et 5 , Sulisobenzone (Uvinul MS40) 5% (in acid form) 10%
Methylene bis-benzotriazolyl tetramethylbutylphenol,
Bisoctrizole
(Tinosorb M)
10% 10%
Disodium phenyl dibenzimidazole tetrasulfonate
(Néohéliopan AP)
10%
(in acid form) /
Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine,
Bemotrizinal (Tinosorb S) 10% 10%
Polysilicone 15 (Parsol SLX) 10% /
Titanium dioxide 25% 25%
Diethylamino hydroxybenzoyl hexyl benzoate
(Uvinul A+) 10% /
Table 4. Authorized UV-filters in Europe and in US
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US Europe
1 - Allantoin 0.5 – 2% /
2 - Cocoa butter 50 – 100% /
3 - Cod liver oil 5 – 13.56% /
4 - Dimethicone 1 à 30% /
5 - Glycerin 20 – 45% /
6 - Hard fat 50 – 100% /
7 - Lanolin 12.5 – 50% /
8 - Mineral oil
50%
30 – 35% in combination with
colloidal oatmeal
/
9 - Petrolatum 30% /
10 - White petrolatum 30% /
11 - Aluminium hydroxyde gel 0.15 – 5% Annex III
12 - Calamine 1 - 25% /
13 - Kaolin 4 – 20% /
14 - Zinc acetate 0.1 – 2% Annex Colorant (CI 77950)
15 - Zinc carbonate 0.2 – 2% Annex III ( 1% expressed in Zinc)
16 - Zinc oxide 1 – 25% Annex Colorant (CI 77947)
17 - Colloidal oatmeal
0.007% minimum
0.003% minimum in combination
with mineral oil
/
18 - Topical starch 10 – 98% /
19 - Sodium bicarbonate / /
Three ingredient groups in US : group 1 [1 to 10] – group 2 [11 to 16] and group 3 [17]
The active ingredients in each of these groups can be combined only with the other active ingredients in the same group.
Active ingredients in different groups cannot be used in the same drug product. For example, cocoa butter can be
combined with glycerine, but not with aluminium hydroxide gel.
Table 5. Comparative regulation of ingredients called « protectants » in US
2.2.4. Labelling rules
The comments which must be included on the packaging are presented in Table 6. The same
concern for public health governs the labelling rules, no matter which legislation is concerned.
It is a pity that at present, on the packaging of European sun products, there is no clear reference
to the size of the recommended dose of the product which should be applied on the skin. This
lack is currently being studied, and it has to be said that having directions on the packaging
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as to how much of the product should be used would be very useful, as it is known that
consumers do not use as much of the product as they should, on average 4 times less [36]. It
is known that the effect is linked to the dose. A good initiative of the Colipa should be noted
concerning sun protection cosmetics: this committee has in fact created a logo (Figure 1) which
reminds us that the product in question provides protection against UVA rays. A ratio of UVA
efficacy/UVB efficacy equal to or lower than 3 was imposed in order to avoid products which
only protect against UVB rays.
EU Europe
Categories of sunscreens 2 ‹ SPF ≤ 12 : « provides minimal » or
« provides minimum » « minimal » or
« minimum » « protection against »
« sunburn » or « sunburn and
tanning » or “for skin that sunburns
minimally”
12 ≤ SPF ‹ 30 : « provides moderate »
or “moderate” « protection against »
« sunburn » or « sunburn and
tanning » or “for skin that sunburns
easily”
SPF ≥ 30 : « provides high » or “high »
« protection against » « sunburn » or
« sunburn and tanning » or “for skin
highly sensitive sunburn”
SPF : 6 – 10
Low protection
SPF : 15 – 20 – 15
Moderate protection
SPF : 30 – 50
High protection
SPF : 50+
Very high protection
Warnings “When using this product keep out of
eyes. Rinse with water to remove”
“Sto use and ask a doctor if rash or
irritation developps and lasts”
/
Particular allegations « retains SPF after 40 minutes of
activity in the water or sweating or
perspiring »
« retains SPF after 40 minutes of
activity in the water or sweating or
perspiring”
Water resistant
Very water resistant
Quantity to apply « apply » « liberally » or « generously »
or « smoothly » or « evenly »
“”reapply as needed or after towel
drying, swimming, or sweating or
perspiring”
Cas of childrens « children under 6 months of age :
ask a doctor »
No sun exposure before 36 months
Table 6. Labelling of sunscreens
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Figure 1. UVA logo
2.2.5. Procedures to be followed
In Europe, it is just necessary to draw up a file on cosmetics which should remain relatively
short. This is only consulted by authorized personnel from the authorities which are concerned
(AFSSaPS or the Répression des Fraudes [Fraud Prevention]) in case of inspection. The status
of an over-the-counter medicine is very restricting as solid clinical studies must back up the
request for such a status. As an example, we can look at the Anthélios SX® product by the
Laboratoires La Roche Posay whose sale is now authorized in the USA following FDA
approval. The file was backed up by 28 clinical studies including 2500 patients from 6 months
to 65 years of age. It can be said, therefore, that sun products destined for the American market
are ones which have sufficient hindsight in Europe (enough time has lapsed to enable clinical
studies to be compiled). What is more, very few active ingredients are present in the formula:
ecamsule, avobenzone and octocrylene.
2.3. Dosage forms
Sun products come in different dosage forms: liquid forms (oils), thick pasty forms (emulsions
which are referred to as milks or creams according to the texture) and solid forms (sticks). The
most interesting forms are the systems which contain 2 phases enabling hydro- and liposoluble
filters to be incorporated together. The role of the excipient is a minor one, and will have little
influence on the SPF measured. However, it will have an important role to play in terms of
how the product is spread [36], in terms of its substantivity (a sun product must stay on the
surface and the phenomenon of transdermal penetration must be reduced to as little as
possible) [37]. Pickering emulsions are interesting as their formula contains titanium dioxide
which not only carries out the role of an active sun-protection ingredient but also that of an
emulsion stabilizer [38].
2.3.1. Liquid forms: Sun oils and waters
Oils and waters are single-phase systems and are forms which provide minimal sun protection.
Generally, they are composed of thermal water to which a hydrophilic filter is added. As for
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sun oils, they are generally composed of a vegetal oil, such as monoi, for example, or coconut
or sesame oil, to which one or more lipophilic filters is added.
2.3.2. Paste forms: Gels and emulsions
Gels, often called "sun jellies", are forms which are not very photoprotective. These are aqueous
or hydroalcoholic phases (the latter being quite incompatible with exposure to the sun!) which
are thickened using a derivative of cellulose (carboxymethyl cellulose, for example) or a
derivative of carboxyvinylic acid and incorporating a hydrophilic filter.
As for emulsions, they are the most commonly used dosage forms in the field of topical
photoprotection. According to their viscosity and therefore their use limited to small surface
areas (the face for example), or adapted to large areas (the whole body), they are referred to
either as milks or creams. Whichever they may be, these forms provide a wide range of SPF
values, going up to 50+. As they are two phase systems, (containing a hydrophilic phase and
a lipophilic phase), they offer the great advantage of enabling all sorts of combinations of filters
(hydro- and lipophilic ones) to which screens (such as zinc oxide and titanium dioxide) can be
added. Lipophilic aqueous emulsions (W/O) are to be preferred due to their water-resistant
character.
2.3.3. Solid forms: Sticks
The stick is a highly photoprotective cosmetic form which is adapted for application on small
surface areas, obviously for the lips, and also for the sides of the nose, for example. A stick is
made up of a mixture of waxes (animal wax, such as bees' wax, or vegetable waxes such as
carnauba wax) which act as a "spine" for the finished product and give it its hardness, fats
(vaseline, shea butter, etc.) and oils (sweet almond, jojoba, etc.). Lipophilic filters and screens
are then incorporated into this mixture.
2.4. Determining the efficacy
2.4.1. Efficacy indicators: SPF and UVA-PF
In France, article L 5131-6 of the Public Health Code states that " a cosmetic product can only
be put onto the market free of charge or against payment if the manufacturer, or their repre‐
sentative, or the person for whom the cosmetic product is made […], effectively makes
available to the controlling authorities […] proof of the effects that it is claimed to have, when
it is warranted by the nature of the effect or of the product". As for over-the-counter products,
clinical trials must have been carried out, of course, in order for the product to be able to be
put onto the market, as in this case, it is a medicine.
2.4.1.1. A few words about sun protection factor
The Sun Protection Factor (SPF) is a factor which indicates the efficacy of a sun product
regarding erythema, as UVB rays are 1000 times more erythemogenic than UVA rays [39]. If
we briefly recount the history of sun products, everything started in the 1930's with the
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marketing of a certain number of products containing sun filters (such as benzyl salicylate) [40]
and claiming to prevent sunburn, without being able to evaluate precisely the level of efficacy.
At this time, the product Ambre solaire® by the chemist Eugène Schueller could be found on
the market. At the time, no particular attention was paid to the molecules used and a certain
number of ingredients used were likely to cause what Freund defined for the first time as
Berloque Dermatitis [41]. From the end of the Second World War, the number of companies
involved in the field of sun protection (Coppertone, Piz Buin, etc.) increased, and more and
more knowledge was gained about efficacy. Some errors were committed, however, such as
the Bergasol products (in the 1970's) which were formulated with bergapten, which is a
molecule with photosensitizing properties which are nowadays well-known [42]. The efficacy
indicators which were initially very low, defined by Blum et al in 1945 [43], gradually increased,
eventually reaching the values of 50+ which we know today.
2.4.2. In vivo methods of determination
Currently, whatever the country, protocols can be found which have similar conditions (type
of panel, mass of the product applied, type of lamp used, etc.).
2.4.2.1. Definition of the MED
The FDA defines the MED as the “the quantity of erythema-effective energy (expressed as
joules per square meter) required to produce the first perceptible, redness reaction with clearly
defined borders”.
The Colipa [44] gives its own definition, a precision of time, as we know that sunburn is likely
to develop over a 24-hour period: “The Minimal Erythema Dose in human skin is defined as
the lowest UV dose that produces the first perceptible unambiguous erythema with defined
borders appearing over most of the field of UV exposure, 16 to 24 hours”.
2.4.2.2. Definition of SPF
An individual Sun Protection Factor (SPFi) value for a product is defined as the ratio of the
MED on product protected skin (MEDp) to the MED on unprotected skin (MEDu) of the same
subject:
SPF = MEDp (protected skin) / MEDu (unprotected skin)
The SPF for the product is the arithmetic mean of all valid individual obtained from all subjects
in the test, expressed to one decimal place.
2.4.2.3. Information concerning the volunteers
The comparative elements between the Colipa and the FDA concerning the subjects selected
are presented in Table 7. As we can notice, the selection conditions are very similar. In Europe,
the selection of subjects is made following the visual determining of the phototype of the
subjects and by questioning or by instrumental methods using a chromameter which converts
the colours into a digital code comprising 3 coordinates (Lab system). Using these coordinates,
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we can determine the ITA (Individual Typological Angle) which is proportional to the degree
of pigmentation of the skin. The darker the skin, the smaller the angle [45, 46]. However, it is
regrettable that the minimum number of subjects required by the Colipa in order to obtain
valid results is only 10. The FDA demands double that number, which seems more reasonable.
No notion of latent period between the tests is mentioned by the FDA. It is a pity that the
presence of nevi is not totally unacceptable in the US, indeed, the link between multiple nevi
and melanomas is a well-established fact. The risk of developing a melanoma for a person with
multiple nevi, that is to say between 100 and 120, is 7 times higher than for someone who only
has a few nevi (between 0 and 15) [47, 48, 49]. It would be interesting, therefore, to limit the
tests to subjects with a low number of nevi. It also seems absurd to find references to people
with phototype I skin, as these subjects are at risk of developing skin cancer [50]. It therefore
appears useless to subject them to UV irradiation, whether it be natural or artificial.
Colipa FDA
Phototype - Phototype I, II or III according to
Fitzpatrick
- or ITA°value > 28° by colorimetric
methods
- Only fair-skin subjects with skin types I, II, and
III using the following guidelines :
I – always burns easily; never tans (sensitive)
II – Always burns easily; tans minimally (sensitive)
III – Burns moderately; tans gradually (light
brown) (normal)
(Skin type and Sunburn and tanning history
based on first 30 to 45 minutes sun exposure
after a winter season of no sun exposure)
Medical
characteristics
- Exclusion of sensitive subjects (previous
history of abnormal response to the sun)
- children
- pregnant or lactating women
- subjects taking medication with
photosensitising potential
- subjects with dermatological problems
- subjects accustomed to using tanning
beds
- subjects having marks, blemishes or nevi
or presenting with existing sun damage
- Exclusion of sensitive subjects (previous history
of abnormal response to the sun)
- the presence of nevi, blemishes, or moles wille
be acceptable if the physician’s judgement they
will not interfere with the study results.
Written consent - Informed, written (signature) consent - Legally effective written informed consent
Number of
volunteers
- minimum 10 (10 valid results)
- maximum 20
- minimum 20 (20 subjects must produce valid
data for analysis)
- maximum 25
Frequency of
participation in
tests
- Latence time of 2 months /
Table 7. Characteristics of the panel
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A test will be considered as valid if “confidence limits (95% Confidence Interval) for the mean
SPF should fall within the range of ± 17% of the mean SPF”. In the case of a high level of
uncertainty, the subject(s) having generated over-large standard deviation are excluded from
the study.
2.4.2.4. The conditions of the test
2.4.2.4.1. Test area
The irradiation sites are similar whether it be for the Colipa or the FDA: between the scapula
line and the waist. The minimum surface area required according to the FDA is one of 50cm²
for an area, and of 4 to 5 cm² for a subsite area. For the Colipa, the minimum area for a product
application site shall be 30 cm2 and the maximum shall be 60 cm2.
The dose of the product applied on the skin is 2 mg/cm2 (this dose is universally recognized).
The Colipa specifies that the quantity of the product applied on the skin before spreading
should be 2 mg/cm2 ± 2.5% (the sensitivity of the scales should be at least 0.0001 g, ie. with at
least 4 decimal places). The product should be applied with a finger-cot and can be deposited
with a syringe for liquid products, or for products which can be made into liquids after being
warmed slightly. The Colipa states a quantity of 15 drops of the product for 30 cm2 in order to
obtain a homogenous distribution of the product. The application time is also measured and
should be between 20 and 50 seconds according to the surface area in question. The products
are applied in a randomized way.
The Colipa makes a clarification regarding the proximity of the test sites: there must be a
minimum distance of 1 cm between the borders of adjacent product application sites.
A variable latent period is respected between application and irradiation: 15 minutes (FDA)
or 15 to 30 minutes (Colipa).
The lack of information concerning the quantity of the product present on the skin after
spreading is also regrettable. No in vivo method states the quantity of the product which
remains on the finger-cot, a quantity which varies according to the nature of the product which
is applied (a product which is either fluid or pasty, with either sticky or, on the contrary, film-
forming ingredients).
The conditions of temperature of the room in which the tests are carried out are drawn up by
the Colipa. It is recommended to use rooms with air-conditioning. However, the temperature
range is quite wide (18 to 26°C).
2.4.2.4.2. The characteristics of the lamp used
The characteristics in terms of quality of emitted UV rays, of total irradiance and the uniformity
of the beam are similar in Europe to the United States. The characteristics are the following: a
solar simulator used for determining the SPF of a sunscreen product should be filtered so that
it provides a continuous emission spectrum from 290 to 400 nm similar to sunlight at sea level
from the sun at a zenith. No emission fluctuations should be seen through time and the
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intensity of irradiation should be as uniform as possible. The material should be subjected to
frequent radiometric controls.
The source of illumination should be either a tungsten light bulb or a warm white fluorescent
light bulb that provides a level of illumination at the test site within the range of 450 to 550 lux
(FDA) or a xenon arc solar simulator with a filtering system.
2.4.2.4.3. Determining the MED in practice
A series of UV radiation exposures expressed as joules per square meter is administered to the
each subject with an accurately-calibrated solar simulator.
A Colipa – FDA comparison is presented in Table 8. The FDA suggests some examples for SPF
from 8 to 15.
Colipa FDA
Unprotected skin - a minimum of 5 sub-sites centred
on the estimated MEDu shall be
exposed with incremental UV doses
using a recommended geometric
progression of either 1.12 or 1.25.
- a series of 5 exposures should be
administered to the untreated skin.
The doses selected shall be a
geometric series represented by
(1.25n), wherein each exposure time
interval is 25% greater than the
previous time .
Protected skin - The centre of the UV dose range is
that of the unprotected MED
multiplied by the expected SPF of
the product.
- a minimum of 5 sub-sites centred
on the estimated MEDu shall be
exposed with incremental UV doses
using a recommended geometric
progression of either 1.12 or 1.25
- 7 exposures
- the doses selected shall consist of a
geometric series of five exposures
where the middle exposure is placed
to yield the expected SPF plus two
other exposures placed
symmetrically around the middle
exposure.
Measure - 24 h after exposure - 24 h after exposure
Table 8. MED determination
For a product with an SPF of 8, given that the MED must correspond to the dose or to the
median time, it will be surrounded with values obtained according to a geometric sequence at
a rate of 1.25:
0.64 x MED – 0.80 x MED – 1 MED – 1.25 Med – 1.56 MED
Furthermore, 2 doses placed symmetrically in relation to the median dose are added, here:
0.9 x MED and 1.10 x MED
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Sometimes, we speak in terms of SED (Standard Erythema Dose) which corresponds to the
efficient erythemogenic exposure. For human beings, an SED corresponds to an exposure of
100 j/m2. Caucasian subjects have an MED of between 150 j/m2 (or 1.5 SED) and 600 j/m2 (or 6.0
SED) according to the phototypes (as the Caucasian type includes phototypes which differ as
much as phototypes I and IV) [51]. We can speak indifferently either in terms of dose or time.
2.4.2.5. Determining the UVA protection factor (UVA-FP)
2.4.2.5.1. Introduction
Although the protocol of determining the SPF is very clearly defined, both in Europe and in
America, this is not the case concerning the UVA protection factor [52]. The two most fre‐
quently used methods are the IPD (Immediate Pigment Darkening) and PPD (Persistent
Pigment Darkening) methods. Since 2007, taking the UVA protection in a sunscreen into
account has become a necessity in Europe, with the establishing of 5 categories corresponding
to no, low, medium, high and highest UVA protection [53].
2.4.2.5.2.- IPD and PPD methods
These methods are based on the evaluation of the Meirowski phenomenon consecutive to the
action of UVA rays. To do this, a halide lamp or a xenon arc lamp equipped with UVB filters
is used. The subjects who are recruited have phototypes III and IV because they are likely to
develop a tan in the evening. If the reading takes place at a maximum of 2 hours after irradi‐
ation, we refer to the IPD (immediate pigment darkening) method. If the reading is taken later,
we can refer to it as the PPD (persistant pigment darkening) method [54, 55, 56].
The UVA-PF is defined according to:
UVA-PF = MIPDDprotected skin / DMIPDDunprotected skin
with MIPDD, Minimum Immediate Pigment Darkening Dose
or :
UVA-PF = MPPDDprotected skin / MPPDDunprotected skin
with MPPDD, the Minimal Persistent Pigment Darkening Dose.
2.4.3. In vitro methods of determining the efficacy of sun products
2.4.3.1. Determining the SPF in vitro
There is no official method in this field. All the methods which are proposed are spectropho‐
tometric methods based on the Beer Lambert law which links the absorbance of a sample to
its concentration of active molecules. The principal of determining the SPF in vitro is based on
measuring the transmittance of a sun product applied on various kinds of support. In the
1980's, Sayre and Agin studied different spectral light sources enabling them to correlate the
results obtained respectively by in vitro and in vivo methods [58]. The first trials were carried
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out on supports such as certain animal skins (mice and pigs) or even on human skin. In 1989,
Diffey and Robson tested a new substrate called Transpore® (3M, St Paul, US), a cheap adhesive
system [59]. Its supple texture means that it must be placed on a rigid plate (such as quartz).
The main disadvantage for its use is that it has varying sizes of pores depending on the part
of the roll of the material which is used (which means that the first and last 60cm of the roll
must be discarded and that the pores vary in size from one roll to the next. It is interesting for
testing simple formulas, however, the results obtained are very different from those observed
in vivo for formulas including complex mixtures of filters [60]. The quartz plates can also be
used alone. They have 2 disadvantages: they are expensive and as they are not disposable, they
must be rigorously cleaned between 2 series of measurements. Even though they are able to
be used in research, they seem to be quite unsuitable for industrial use [61]. Skin substitutes
(Vitroskin®) provide an interesting analogy with real skin, but they are expensive and they
have a limited length of use once they have been rehydrated [62]. Different synthetic substrates
are currently used, such as polyvinylchloride film (Saran Wrap®), Teflon [63] and polyme‐
thylmethacrylate (PMMA) [64, 65]. Whatever support is chosen, its efficacy in UVB light is
determined by calculation, by effecting the convolution product of the spectrum of the source,
of the spectrum transmitted through the sample and of the spectrum of the erythemogenic
efficacy (figure 2) [66] and by integrating the area under the curve in the following formula:
SPF =
∑
290
400 EλSλΔλ
∑
290
400 EλSλTλΔλ
with Eλ being the spectral erythemogenic efficacy (International Committee on Illumination),
Sλ being solar spectral irradiance and Tλ being the spectral transmittance of the sample.
2.4.3.2. In vitro determination of the UVA-PF
The Colipa published guidelines in 2007 for determining the UVA index in vitro. The initial
UVA-PF is calculated using the UV absorbance spectrum which was adjusted to the labelled
SPF. Sunscreen samples were then exposed to a single UV dose of 1.2 times the initial UVA-
PF (in joules/m²). The final UVA-PF values for the samples were calculated from the adjusted
absorbance spectrum after irradiation [67]. Other calculations made are those of the SPF/UVA-
PF ratio, which must be lower than 3, and the critical wavelength λc (the wavelength under
which the product is 90% effective) which must be above or equal to 370 nm according to the
recommendations of the AFSSaPS.
At the same time, the FDA suggested an in vitro method for determining the efficacy in UVA
rays. The in vitro UVA proposed is based on measurement of UV transmission through a
sunscreen film. The absorbance curve was obtained, in this case after pre-irradiation with a
UV dose specified as two thirds of the SPF in Minimal Erythemal Doses (MEDs) (1 MED = 20
SED), and the mean absorbance in the UVA1 range from 340 to 400 nm and the entire UV range
from 290 to 400 nm were determined. The ratio of mean UVA1 absorbance to mean absorbance
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determines the rating. There are 4 categories (ratio ≥ 0.2 “low – 1 star” ; ratio ≥ 0.4 “medium –
2 stars” ; ratio ≥ 0.7 “high – 4 stars” ; ratio > 0.95 “highest – 4 stars”) [68].
2.5. Determining water-resistance and photostability
2.5.1. Determining water-resistance
The technique and the quantity of the product applied on the skin play an important role in
the obtained level of photoprotection. The same applies to the water-resistance of products [69]
which is an important element to take into account when choosing a product which is going
to be used on the beach.
2.5.1.1. In vivo methods of determining water-resistance
The FDA and the Colipa propose protocols for determining the water-resistance of sun
products [70, 71].
The principal is the same in both cases. The subjects are immersed in a swimming pool or a
jacuzzi, etc. On the other hand, the way of interpreting the results is not done in the same way
in Europe and in the United States.
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Figure 2. Variations of weighting coefficients for each wavelength concerning erythema and non-melanoma skin can‐
cer (Norme CEI 60335-2-27, 2002)
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In the United States, a product can display the words "water resistant" on the packaging and
the SPF mentioned is the SPF obtained after 2 successive baths of 20 minutes. For the product
to qualify as being "very water resistant", it must have undergone a test of 4 successive baths
of 20 minutes.
In Europe, a certain number of pre-requisites must be checked before the test is carried out to
ensure that the incertitude is less than 17% of the average SPF. A percentage of water resistance
is calculated by comparing the SPF obtained after 2 successive baths of 20 minutes and the
initial SPF. If the percentage is higher than or equal to 50% of the initial SPF, then the product
is declared as being "water resistant". In the same way, a product is declared as being "very
water resistant" if after 80 minutes of immersion (4 periods of 20 minutes) the percentage of
water resistance is higher than or equal to 50%. In both cases, the SPF displayed is the initial
one (obtained before immersion).
2.5.1.2. In vitro method of determining water resistance
Very few studies exist concerning the development of in vitro techniques. Work by Choquenet
et al can be quoted, which, by analogy with the Colipa method, provide the necessary
conditions for distinguishing water resistant products from products which can be washed
away with water [72]. The authors recommend immersing the PMMA plates, coated with the
product which is to be tested, in a bath of distilled water, shaken gently (5 L.min-1) and at a
temperature of 29 ± 2°C. The creams are applied to the PMMA plates and their SPF is measured
using an integrating sphere spectrophotometer (Labsphère UV1000S) before and after
immersion. As in the in vivo method, the product is deemed "water resistant" if the SPF after
the bath is at least 50% of the initial SPF.
2.5.2. Determining the photostability of sun products
The photostability of sun products is an important criterion for two reasons: if the product is
not photostable, its efficacy will decrease rapidly over time and the subject will thus no longer
be sufficiently protected. Furthermore, the production of photo-oxidation products can lead
to problems of skin tolerance [73]. It is advisable therefore to study the photodegradation
profile of the filters incorporated into the excipients and to determine efficacy kinetics over
time. Certain filters such as PABA [74] or benzophenones [75] are reputed to be very photo‐
stable. Other filters which are not very photostable, such as avobenzone, have a varying degree
of stability according to the composition of the medium [76]. The filters can be studied alone
or in a mixture, they can be irradiated after being placed on a glass plate in the UVB/UVA field
and their photostability can be assessed by the dose of HPLC [77] or they can be studied in
vivo. L’Oréal carried out an in vivo study in 2008 on 5 subjects. This study consisted in applying
a product (SPF 15 ; FP-UVA 15) onto the volunteers' skin, formulated with 3 organic filters,
octocrylene, avobenzone and Mexoryl SX®, irradiating them at doses ranging from 64 to 200%
of the SPF, in retrieving the product from the skin and then dosing the filters. There was no
significant difference between the rate of filters before and after irradiation, even for the high
doses (200% SPF ie. 30 MED) [78]. A systematic study of the 18 UVB filters which are authorized
in Europe enabled the filters to be ranked in ascending order of photostability. The filters which
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retain more than 90% of their efficacy after irradiation in a solar simulator are deemed to be
photostable. Eight filters (PABA, Oxybenzone, Phenilbenzimidazole sulfonic acid, Octocry‐
lene, Diethylhexylbutamidotriazine, 4-methylbenzylidene camphor, Benzophenone-5 and
Methylene bis-benzotriazolyl tetramethylbutylphenol) appear to be interesting and likely to
stabilize the formulas they are incorporated into [79].
2.6. Active ingredients
There are two categories of active ingredients, inorganic filters, also known as screens, and
organic filters.
2.6.1. Inorganic filters or screens
Two screens could be used: titanium dioxide and zinc oxide which act by reflecting the ultra-
violet rays. Both take the form of an inert, particularly photostable white powder [80, 81]. They
were used for a long time in pigmentation, but were considered not to be very effective and
were not very aesthetic due to the fact that they leave a white film on the skin sometimes called
the "Pierrot's mask". The micronization of powders brought a solution to these 2 disadvantages
[82, 83]. The reduction of the size of the particles from 200 nm to 15 nm makes the products
more acceptable and coating them makes them disperse more easily in the chosen excipient.
However, the reduction of the size of the particles raises certain questions, namely as to
whether they can cross the skin barrier. Studies on pig skin show that micro-thin zinc oxide
and titanium dioxide powders do not penetrate into the skin [84]. Similar results were obtained
in vivo by the stripping method and showed that zinc oxide (Z-Cote Max® BASF) was restricted
to the superficial layers of the epidermis, namely the Stratum corneum [85]. As for harmlessness,
the results contrast. Some people argue that a risk exists, zinc oxide could have potentially
genotoxic effects on human epidermal cells [86] and titanium dioxide could be cytotoxic and
genotoxic on cell cultures (hamster ovary cells) [87]. For others, these ingredients are totally
safe [88, 89]. Concerning efficacy, titanium dioxide proves to be the most efficient, as it gives
an SPF value of 10 (Eusolex TS®) as opposed to 5 for zinc oxide (Z-Cote Max®) for the same
incorporation percentage of 10%. It can be noted, however, that zinc oxide has a wider
spectrum as it proves to be as efficient in the UVA field as in the UVB field, contrary to titanium
dioxide which is 2.5 times less efficient in UVA rays as in UVB rays [90].
2.6.2. Organic filters
2.6.2.1. Introduction
It is a question of molecules which have one or more aromatic cycles associated with a
substituent electron donor and/or an unsaturated hydrocarbon chain. These molecules are
characterized by a chromophoric group which absorbs the incident photons' energy at certain
wavelengths. It is said that the filters are selective, as they only absorb energy in a well-defined
range of the UV spectrum. Each filter is thus characterized by its wavelength of maximum
absorption (λmax).
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2.6.2.2. The main families and their characteristics
PABA (λmax = 309 nm) is now banned in Europe due to the fact that it is highly allergenic [91].
Its derivatives (PEG-25 PABA and Octyldimethyl PABA) are less allergenic and are still
authorized in Europe. They are some examples of the few hydrosoluble filters available.
According to the grafting which was carried out, the efficacy is variable. Octyldimethyl PABA
(Padimate O) enables an SPF value of 9 to be attained for 8% of incorporation, and PEG-25
PABA gives an SPF of 4 for 10% [92].
Cinnamates are the most widely used UVB filters. As an example, we can give octylmethox‐
ycinnamate (OMC) (λmax = 310 nm). Indeed, it is found in a large number of products on the
market. Cinnamates are well tolerated, even though they are linked with the notion of being
endocrine disruptors. It should be remembered however, that OMC has 140,000 times less
affinity for α receptors and 500,000 times less affinity for β oestrogen receptors than βestradiol,
the standard oestrogen [93] and that its uterotrophic effects in animals is judged to be very low
[94]. Cinnamic esters are quite efficient filters as they generate approximately 1 SPF unit per
percentage of use [92].
Salicylates are poor photoprotectors. We can mention in particular homomenthyl salicylate or
homosalate (λmax = 306 nm) which, when incorporated into the recommended excipient at 8%,
constitutes the FDA standard and which enables an average SPF of 4.47 (4.47 ± 1.279) to be
reached. It is practically non-existent in European products. Certain publications report that
octisalate (or octyl salicylate) has a proliferative effect on MCF-7 cells in breast cancer [95].
Benzophenones are wide spectrum filters which give 2 maxima of absorption in UV rays, one
of 285 nm and the other close to 325 nm. As examples, we can mention benzophenone-3 (or
oxybenzone) and benzophenone-4 and 5. Although they are not very efficient filters (SPF of 3
to 10% for oxybenzone and 4 to 5% for benzophenone-4), they are interesting, however, because
they are very stable. Their low substantivity is a disadvantage, as is their poor tolerance
(frequent allergic reactions for oxybezone) [96, 97]. Questions are being raised in other respects,
as there could be a potentialization of the transdermic penetration of oxybenzone by a
frequently associated repellent, DEET (NN diethyl-m-toluamide) but opinions are divided [98,
99]. What is certain is that oxybenzone is a filter which is found in the organism after topical
application. It is known that 1 to 2% of the oxybenzone contained in a formula is absorbed
after 10 hours. It is advised that these products should not be applied over large surfaces and
that repeated applications should be avoided [100]. As for formulation, certain ingredients
such as Transcutol® (diethylene glycol monoethyl ether) could be looked for, which increase
substantivity without favouring crossing the skin barrier [101]. These are not therefore filters
that should be rejected, but rather filters that should be used with care.
Triazines and derivatives (Bemotrizinal or Tinosorb S® -305 and 360 nm- and Bisoctrizole
or Tinosorb M® -310 et 340 nm) are safe from a toxicological point of view [102]. They are
marketed by a company called Ciba and are synergic. It is thus particularly interesting to
combine them in the same formula. Bisoctrizole is both the best UVB and the best UVA
filter on the market [92].
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Mexoryls®  and more precisely Mexoryl SX®  are derivatives of camphor. The latter is the
only Mexoryl®  of  the series  to  be authorized in the United States.  It  is  presented as  an
interesting filter regarding protection from skin damage caused by UVA rays both in vitro
and in vivo [103, 104].
Concerning UVA filters, avobenzone is widely used and its lack of stability can be compen‐
sated for by combining it with other filters. Encapsulation, although fuelling many publica‐
tions, has not enabled any industrial application so far [105, 106]. Neoheliopan AP® and Uvinul
A+® are not authorized in the United States yet.
It is a pity that 3-benzylidene camphor (limited to 2%) is still authorized in Europe, as at this
dose it is almost inefficient and it is also suspected of being an endocrine disruptor [107, 108].
2.6.3. Molecules of interest
Although a certain number of authors claim that the toxicity of organic filters is irrefutable,
the same cannot be said for the others. The potential endocrine effect of certain filters is not
conclusive and the controversy concerning parabens which has shaken the scientific com‐
munity [109] lead us to believe that in the field, it is necessary to be prudent and indispensable
ingredients for photoprotection should not be too hastily discredited. However, confronted
with these threats, it would be advisable to find new filters, especially using plants as a source,
as well as ingredients which could complete the action thanks to their original properties.
We could mention, for example, boldine, an alkaloid from the boldo tree, which has been
known for a long time for its antioxidant properties [110] and more recently for a potential
photoprotective effect [111]. Aromatic compounds contained in certain lichens [1 chloropan‐
narine, epiphorelic acid I and II, calicine) prove in vitro to be of a level of efficacy comparable
to that of OMC [112]. Flavonoids, natural colorants of many plants prove to be an interesting
family too with chlorogenic acid in particular (SPF = 10), baicaline (SPF = 8), luteoline (SPF =
7), apigenine (SPF = 7), puerarine (SPF = 6) for a usage dose of 10% [113]. Coming from the sea,
mycosporine-like aminoacids seem to be interesting in particular with a potential photopro‐
tective effect in the UVA field [114, 115, 116].
3. Care products and make-up with SPF
Recently, there has been a wave of care products and make-up with SPF on the market, their
SPF being mainly around 15. The justification for this is found in publications which state that
there is a beneficial effect of using filters on a daily basis in order to prevent skin ageing and
in particular using a mixture of avobenzone (1.5%) - ecamsule (1.5%) - octocrylene (4%) [117].
Even if we know very well that UV rays are responsible for actinic ageing, the daily use of
products containing filters does not seem to be a good thing. It appears that filters, even though
they are active, sometimes have adverse effects. They must be kept, therefore, for use in sun
care products, all the more so as these other care products are not sun care products, so do not
have to obey the same rules, namely those concerning the SPF / UVA-PF ratio and the critical
wavelength [118].
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4. Conclusion
Given the consequences for the skin of exposure to the sun, it seems necessary to ensure
effective photoprotection. We have seen the various dosage forms, which offer a wide range
of products adapted to the site of application. According to the quality-quantity of the product,
the level of efficacy can vary greatly. The status of the products in itself is not unique, on one
side of the Atlantic or the other, as cosmetics, medical devices and OTC medicines can be found.
On the other hand, the methods for determining the efficacy of these products are almost
universal.
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